At a glance
ClinicalIndex Comparison RecordN/ACompleted· 463 enrolled
Drug / intervention
Peginterferon alfa-2a +1 moredrug
Likely dose
Peginterferon alfa-2a 180 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Interventional Trial of Pegasys/Copegus in HCV Patients for 12 Months
In Brief
An observational study evaluating Peginterferon alfa-2a and Ribavirin for Hepatitis C. Completed, enrolled 463 participants across 1 site.
Detailed Summary
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
Primary CompletionDec 2014
First PostedAug 2015
TodayJul 2026
First PostedAug 4, 2015
Enrollment StartNov 1, 2008
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 10.9 years ago
Interventions
Peginterferon alfa-2adrug
180 micrograms subcutaneous weekly for 48 weeks.
Ribavirindrug
1000-1600 mg day orally for 48 weeks.